Novel microneutralization assay for HCMV using automated data collection and analysisABAI, Anna Maria; SMITH, Larry R; WLOCH, Mary K et al.Journal of immunological methods. 2007, Vol 322, Num 1-2, pp 82-93, issn 0022-1759, 12 p.Article

Safety and Immunogenicity of a Bivalent Cytomegalovirus DNA Vaccine in Healthy Adult Subjects. CommentaryGO, Vera; POLLARD, Richard B; NAKAMURA, Ryotaro et al.The Journal of infectious diseases. 2008, Vol 197, Num 12, issn 0022-1899, 1631-1642 [12 p.]Article

Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responsesMEGATI, Shakuntala; GARCIA-HAND, Dorys; WEINER, David B et al.Vaccine. 2008, Vol 26, Num 40, pp 5083-5094, issn 0264-410X, 12 p.Conference Paper

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trialKHARFAN-DABAJA, Mohamed A; BOECKH, Michael; WILCK, Marissa B et al.Lancet. Infectious diseases (print). 2012, Vol 12, Num 4, pp 290-299, issn 1473-3099, 10 p.Article

Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic miceEIBEN, Gretchen L; VELDERS, Markwin P; SCHREIBER, Hans et al.Cancer research (Baltimore). 2002, Vol 62, Num 20, pp 5792-5799, issn 0008-5472, 8 p.Article

Eradication of established tumors by vaccination with venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNAVELDERS, Markwin P; MCELHINEY, Sue; CASSETTI, Maria Cristina et al.Cancer research (Baltimore). 2001, Vol 61, Num 21, pp 7861-7867, issn 0008-5472Article